About ALK

World leader in allergy immunotherapy

ALK is a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies

A century of helping severe allergy sufferers

ALK's heritage
Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, together with our global partners, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
ALK's production
As a company whose products touch the lives and affect the well-being of people around the world, we are committed to maintaining the highest standards.
ALK's partners
We have has entered into partnership agreements with Torii, Abbott and Seqirus to commercialise allergy immunotherapy tablets in Japan, Russia and South-East Asia, and Australia and New Zealand, respectively.
ALK's owners
As of June 2016, the Lundbeck Foundation is the largest and controlling shareholder of ALK, owning 67% of the votes (40% of the capital). The foundation’s uses the return on its investment in ALK to contribute to society.
Last updated: 2016.08.31